CYTISINE is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CYTISINE is the permanent cessation of the nicotine-containing products use.
CYTISINE (also known as cytisinicline). Access the full Summary of Product Characteristics via Consilient Health website or eMC
CYTISINE is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CYTISINE is the permanent cessation of the nicotine-containing products use.
CYTISINE (also known as cytisinicline). Access the full Summary of Product Characteristics via Consilient Health website or eMC
UPDATES AND RESOURCES
Cytisine now an option recommended by NICE!
NICE guideline NG209 has been updated to include Cytisine (also known as cytisinicline).¹ Cytisine has been classified as among the "more likely" interventions to result in successful quitting for UK smokers in the updated NICE NG209 guidelines.¹ The NICE Guidelines mandate that healthcare providers ensure Cytisine is made available to smokers as a treatment option alongside other current therapies. To read the full updated guidance Click here Cytisine, an effective treatment and supported by decades of use in Eastern Europe, is now endorsed by NICE giving healthcare professionals an additional option for smoking cessation1-4 1. NICE NG209. Tobacco: preventing uptake, promoting quitting and treating dependence. https://www.nice.org.uk/guidance/ng209 2. Cytisine Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/15789/ 3. Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ. 2013 Aug 23;347:f5198. doi: 10.1136/bmj.f5198. PMID: 23974638. 4. Karnieg T et al. Cytisine for smoking cessation. CMAJ: 2018 Cited at: https://www.cmaj.ca/content/190/19/e596
Smoking cessation webinar: 17th September 2024
Consilient Health ran a smoking cessation webinar on the topic of: Now is the time: Seizing new opportunities to treat tobacco dependence! You can find a link to the recording of the webinar and the slides below: Webinar recording Webinar slides The webinar took place on the 17th of September 2024. We had two excellent speakers in Professor Matthew Evison and Louise Ross. The webinar was designed for healthcare professionals looking to make a significant impact in their smoking cessation services. With the availability of a range of treatments, coupled with increased government funding, there has never been a better time to enhance your practice. We have discussed the role of different interventions and provided practical advice on how to leverage these developments for maximum patient benefit. This webinar has been organised and funded by Consilient Heath (UK) Ltd and is intended for UK healthcare professionals and other relevant decision makers involved in the delivery of smoking cessation services. Please be informed that product information was discussed at this event.
AWMSG recommends Cytisine as an option for smoking cessation
Following a directed appraisal by All Wales Medicines Strategy Group, Cytisine (cytisinicline) is recommended as an option for use within NHS Wales for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. Click here to access
1. NICE Guideline [NG209] https://www.nice.org.uk/guidance/ng209
